Full Press Release Details
Pharmaceuticals Presents Results of Oral Administration of
of Concept Pharmacodynamic Study in Dogs
suggests that the GLP-1analog exenatide -4 when combined with
promoters is absorbed through the gastrointestinal tract and retains its
Israel - November 14, 2008- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB;
developer of proprietary drug delivery systems, presented the results today
its exploratory study entitled "Enteral Administration of Exenatide-4; Proof of
Concept Pharmacodynamic Study in Dogs" at the Diabetes Technology Society's
Conference in Bethesda, Maryland.
drug delivery technology is being utilized for the oral delivery of polypeptides
and proteins. The Company previously demonstrated that using its proprietary
technology enables the delivery of insulin when administered orally.
-4 is a GLP-1 analog belonging to a new family of drugs referred to as the
incretin mimetics. In addition to exenatide-4, incretin mimetics include
liraglutide and a number of other GLP-1 analogs under development.
Incretins are produced in the intestines and are released in response to
meals. Incretins stimulate insulin secretions from the pancreas as well as
gastric emptying. This has the effect of reducing blood glucose, which is
central in the management of diabetes. Incretins have also been associated
reduction in appetite and may bring about gradual weight loss. Further,
incretins appear to promote beta-cell regeneration and survival.
was conducted in dogs and the absorption of exenatide was assessed by measuring
the effect of exenatide-4 on glucose absorption after oral glucose
administration. Control experiments consisted of oral administration of the
amount of glucose but without exenatide-4. Two doses of exenatide -4 were tested
and the drug was administered 30 minutes prior to the oral glucose load. The
study suggested that exenatide-4 when combined with Oramed's absorption
promoters significantly reduces glucose absorption and does so in a dose
proportional manner.
exenatide-4 and all other GLP1 analogs are only available as injections. An
dosage form such as a tablet or capsule that would replace the injection is
likely to broaden the use of these important drugs and foster compliance and
adherence among patients. Furthermore, it is plausible that the oral route
administration may convey physiological advantages for exenatide-4 and other
analogs as it replicates the physiological route of incretin absorption, from
the gut and conveyed to the portal vein and liver.
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in Jerusalem.
more information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Finn Israel for Oramed